price
corpor client peel hunt
healthtech set transform healthcar
estim world data healthcar relat oecd countri spend healthcar analys
healthcar big data applic ai offer huge opportun improv patient outcom enhanc discoveri research
earli demonstr capabl includ sensyn reduc cardiac arrest oxford hospit month
deepmind abl identifi eye diseas moorfield hospit quickli effici human counterpart
ai cutting-edg technolog estim grow compound-annual-growth-rate healthcar particularli excit area within googl paid
london-bas start-up deepmind roch recent complet acquisit flatiron health
suggest way play
sensyn unlock valu untap uk sovereign asset time spiral pressur healthcar sensyn
leverag expertis pharma nh alongsid specialist ai clinic ai unlock valu unrival nh
data-set sensyn health trust partner nh work close clinician research improv patient care qualiti
reduc care cost drive new avenu research pharma base preced set recent deal roche/flatiron
sensyn could valu upward vs current market valuat base intrins valuat patient-record
sensyn aim acceler discoveri research improv care analysi real world evid anonymis
patient data compani sell patient data contrast peer sensyn help nh sustain monetis
data without lose control use establish link nh recognis best-in-class busi model easi
other replic number upcom catalyst drive valuat compani describ intent sign
nh agreement and/or commerci pharma deal come month find recent initi note
detail healthcar ai landscap listen new podcast seri practition podcast
document must treat market commun purpos direct prepar accord legal requir
design promot independ research subject prohibit deal ahead dissemin invest research
case miss key healthcar news flow talk
sensyn dock station nh pharma
initi sensyn health buy recommend tp sensyn dock station nh pharma aim
acceler discoveri research improv care analysi real world evid anonymis patient data compani alreadi shown
patient benefit uk hospit power analysi pharma august rais ipo nh one biggest collect
single-provid data cradle-to-grav popul peopl sensyn alreadi sign four strateg agreement nh trust
demonstr role trust partner sustain monetis uk sovereign asset unrival nh data-set
upgrad buy
upgrad circassia buy show revenu track meet full-year expect ii impress cost contain reinforc confid
self-fund profit iii strong oper leverag top-lin inflect sight circassia deliv revenu
repres peel hunt consensu full-year revenu estim despit temporari headwind impli
compani well track meet full-year forecast outflow period also impress demonstr success
circassia cost contain effort leav track meet beat full-year target upsid unchang valuat move
shield new deal bring clariti cash runway
reinstat forecast back recent announc commercialis deal norgin compris exclus licens agreement
commercialis feraccru europ australia new zealand deal bring clariti shield cash runway limit risk extern fund
requir new forecast even consid like commercialis deal path profit tp impli upsid
includ noth opportun us market estim could worth anoth partner basi
clinigen announc result septemb result line consensu outlook statement said underli busi
track meet consensu estim clinigen also announc two new acquisit csm iqon up-front payment
respect fund mix debt equiti place accord clinigen csm support three exist major busi unit
bring signific new european infrastructur help achiev ambit region manag potenti brexit impact smaller iqon
acquisit help clinigen revitalis effort recent acquir commerci medicin clinigen said expect acquisit along
recent acquir product modestli accret earn strongli accret thereaft
nh activ dip due chang market share
recent guidanc describ declin nh revenu new sign nh triag analysi nation data
juli howev suggest nh demand materi differ rather chang market share believ
relat geograph varianc hospit footprint first sign ccg clinic commiss group take action reduc
wait list believ spire strategi qualiti win long run nh privat patient move auster perform
primari driver remain cautiou destabilis effect pivot quickli private-pati revenu adjust number
reflect revis guidanc flatten revenu growth move hold tp
sensyn health buy initi
circassia buy hold upgrad
buy deliv sale cash
shield buy
spire healthcar hold
review nh activ dip seem
temporari loss
base busi track deal
corpor client peel hunt
udg underappreci driver growth
like udg strong posit stabl high-vis healthcar servic industri udg undergo
rapid transform align busi myriad opportun aris shake-up
dispos udg suppli chain activ recent non-cor
aquil increas focu faster grow higher-valu add servic rais udg balanc sheet
option high qualiti high growth high margin sharp ashfield commun advisori
busi account oper profit busi udg invest drive
buy recommend valuat methodolog give explicit credit udg strong balanc sheet
demonstr track record value-enhanc invest
sensyn ai capabl gener clinic ai
sensyn dock station nh pharma aim acceler discoveri research
improv care analysi real world evid anonymis patient data
sensyn health potenti chang research develop landscap place patient
patient data forefront research develop process whilst deliv valuabl ai-deriv
insight back pharmaceut compani model dock station connect patient data
clinician pharmaceut industri reduc cost improv care deliveri identifi new
therapeut target biomark
tp deriv blend methodolog use dcf workup base forecast project
deliver ii peer-multipl includ ev/ebitda ev/sal iii metric intrins valu
premium patient-databas
oxford biomedica axov novarti bioverativ deal prove platform
oxford biomedica offer low-risk capex-light pure play gene cell therapi revolut
equiti place fund expans bioprocess facil three major deal novarti bioverativ
axov prove oxb platform well posit growth
importantli believ recent deal axov along major bioverativ novarti
collabor prove success oxford biomedica gene therapi lentivir vector platform believ
translat sizeabl near-term contract partner oxb grant
exclus world-wid licens axov develop commercialis oxb intern pipelin gene therapi
parkinson axo-lenti-pd oxb say expect sign anoth deal intern pipelin
end
corpor client peel hunt
chart one-month ytd total return
fda approv deal us exposur
tabl recent deal within healthcar sector
chart us exposur compani within coverag measur revenu
gener us
chart us healthcar sub-sector perform vs wider
tabl valuat comparison tabl uk small mid-cap healthcar peel hunt coverag
corpor client peel hunt
chart uk healthcar perform vs us eu rel perform
share
multipl comparison complic heterogen sector mani early-stag player
chart ev/sal rel sale growth
chart ev/sal rel sale growth
chart ev/ebitda rel ebitda growth
chart per rel ep growth
chart ev/ebitda rel ebitda growth
chart per rel ep growth
multipl present profit name coverag
price-to-earnings ev/ebitda
chart abc multipl forward price-to-earnings ev/ebitda
chart btg multipl forward price-to-earnings ev/ebitda
chart clin multipl forward price-to-earnings ev/ebitda
chart ctec multipl forward price-to-earnings ev/ebitda
chart hik multipl forward price-to-earnings ev/ebitda
chart spi multipl forward price-to-earnings ev/ebitda
chart udg multipl forward price-to-earnings ev/ebitda
chart vec multipl forward price-to-earnings ev/ebitda
corpor client peel hunt
corpor client peel hunt
chart uk healthcar equip servic uk healthcar perform vs uk
corpor client peel hunt
chart us life scienc tool index use proxi reflect wider perform sub-
chart us med-tech index use proxi reflect wider perform sub-sector
corpor client peel hunt
chart us index use proxi reflect wider perform sub-sector
corpor client peel hunt
recommend distribut octob
research publish last day
recommend structur distribut
peel hunt recommend structur follow
buy expect absolut price perform month
add rang expect absolut price perform month
hold rang expect absolut price perform month
reduc rang expect absolut price perform month
sell expect absolut price perform month
nb recommend primari driver analyst view target price may vari structur due market condit risk profil compani capit return
